NCT01764516

Brief Summary

This study was carried out with the purpose of evaluating zinc and selenium levels in serum of epileptic patients and compare with normal individuals.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2011

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

January 5, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 9, 2013

Completed
Last Updated

January 9, 2013

Status Verified

January 1, 2013

Enrollment Period

4 months

First QC Date

January 5, 2013

Last Update Submit

January 5, 2013

Conditions

Generalized Epileptic

Keywords

zincseleniumserumepilepsyantioxidants

Outcome Measures

Primary Outcomes (1)

  • Study on Serum Zinc and Selenium Levels in Epileptic Patients

    decrement in serum zinc and selenium level

    5 months

Secondary Outcomes (1)

  • Comparison between the selenium levels by gender in two groups

    5 months

Study Arms (6)

Zinc level (micro gram per deciliter)

In all cases

Selenium level (micro gram per deciliter)

In all cases

Zinc level in male (micro gram per deciliter)

Selenium level in male (micro gram per deciliter)

Zinc level in Female (micro gram per decilitre)

Selenium level in Female (micro gram per decilitre)

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

all generalized and single epileptic patiants which were identify for fist time

You may qualify if:

  • New generalized and single epileptic cases patients who accept and sign the approval form of ethical committee non smoker, no trauma, no use of selenium supplement, no use of zinc supplement, no use of vitamin A supplement, no use of vitamin D supplement, no Weight loss, no Diarrhea, no addiction, no alcohol consumption, no use of certain medications,

You may not qualify if:

  • presence of above criteria as well as, generalized and single epileptic cases under treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vali-Asr Hospital

Arak, Markazi Province, Iran

Location

Biospecimen

Retention: NONE RETAINED

Serum were analysis for zinc and selenium

MeSH Terms

Conditions

Epilepsy, GeneralizedEpilepsy

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Heidar N Farahani, PhD

    Department of Biochemistry,Arak medical sciences university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
1 Week
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
faculity of medicine, department of biochemistry

Study Record Dates

First Submitted

January 5, 2013

First Posted

January 9, 2013

Study Start

November 1, 2011

Primary Completion

March 1, 2012

Study Completion

May 1, 2012

Last Updated

January 9, 2013

Record last verified: 2013-01

Locations

IR(1)